James Allison, MD

Education
PGY 3 and Fellowship in Gastroenterology, 06/1974 - Internal Medicine/Gastroenterology, UCSF
PGY 1&2, 05/1971 - Internal Medicine, UCLA
MD, 05/1969 - Medicine, University of Rochester
AB, 05/1964 - French, University of Pennsylvania
Honors and Awards
  • 2017 Achievement Award, American Cancer Society, 2017
  • Distinguished Clinician Award, American Gastroenterological Association (AGA), 2004
  • Crohn’s and Colitis Foundation’s Premier Physician Award, Bay Area Chapter Crohn's and Colitis Foundation, 2003
  • Lowell Beal MD Award, Kaiser Oakland Medical Center, 1996
Publications

  1. Bresalier RS, Senore C, Young GP, Allison J, Benamouzig R, Benton S, Bossuyt PMM, Caro L, Carvalho B, Chiu HM, Coupé VMH, de Klaver W, de Klerk CM, Dekker E, Dolwani S, Fraser CG, Grady W, Guittet L, Gupta S, Halloran SP, Haug U, Hoff G, Itzkowitz S, Kortlever T, Koulaouzidis A, Ladabaum U, Lauby-Secretan B, Leja M, Levin B, Levin TR, Macrae F, Meijer GA, Melson J, O'Morain C, Parry S, Rabeneck L, Ransohoff DF, Sáenz R, Saito H, Sanduleanu-Dascalescu S, Schoen RE, Selby K, Singh H, Steele RJC, Sung JJY, Symonds EL, Winawer SJ, Members of the World Endoscopy Colorectal Cancer Screening New Test Evaluation Expert Working Group. An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles. Gut 2023. PMID: 37463757


  2. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood advances 2023. PMID: 36287248


  3. Hoffman RM, Levy BT, Allison JE. Rising Use of Multitarget Stool DNA Testing for Colorectal Cancer. JAMA network open 2021. PMID: 34473264


  4. Allison J. Why What You May Not Know About Fecal Immunochemical Testing Matters. Annals of internal medicine 2019. PMID: 31307085


  5. Allison J. Why What You May Not Know About Fecal Immunochemical Testing Matters. Annals of internal medicine 2019. PMID: 30802903


  6. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature medicine 2018. PMID: 30361511


  7. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature medicine 2018. PMID: 30297909


  8. Liang PS, Allison J, Ladabaum U, Martinez ME, Murphy CC, Schoen RE, Shaukat A, Tinmouth J, Gupta S. Potential intended and unintended consequences of recommending initiation of colorectal cancer screening at age 45 years. Gastroenterology 2018. PMID: 30138614


  9. Alsayid M, Singh MH, Issaka R, Laleau V, Day L, Lee J, Allison J, Somsouk M. Yield of Colonoscopy After a Positive Result From a Fecal Immunochemical Test OC-Light. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2018. PMID: 29660528


  10. Dominitz JA, Robertson DJ, Ahnen DJ, Allison JE, Antonelli M, Boardman KD, Ciarleglio M, Del Curto BJ, Huang GD, Imperiale TF, Larson MF, Lieberman D, O'Connor T, O'Leary TJ, Peduzzi P, Provenzale D, Shaukat A, Sultan S, Voorhees A, Wallace R, Guarino PD. Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM): Rationale for Study Design. Volume 112 of Issue 11. 2017. PMID: 29016565


  11. Akram A, Juang D, Bustamante R, Liu L, Earles A, Ho SB, Wang-Rodriguez J, Allison JE, Gupta S. Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting. Volume 15 of Issue 8. 2017. PMID: 28167157


  12. Young GP, Senore C, Mandel JS, Allison JE, Atkin WS, Benamouzig R, Bossuyt PM, Silva MD, Guittet L, Halloran SP, Haug U, Hoff G, Itzkowitz SH, Leja M, Levin B, Meijer GA, O'Morain CA, Parry S, Rabeneck L, Rozen P, Saito H, Schoen RE, Seaman HE, Steele RJ, Sung JJ, Winawer SJ. Recommendations for a step-wise comparative approach to the evaluation of new screening tests for colorectal cancer. Volume 122 of Issue 6. Cancer 2016. PMID: 26828588


  14. Fraser CG, Allison JE, Young GP, Halloran SP, Seaman HE. Improving the reporting of evaluations of faecal immunochemical tests for haemoglobin: the FITTER standard and checklist. Volume 24 of Issue 1. 2015. PMID: 24584197


  15. Young GP, Symonds EL, Allison JE, Cole SR, Fraser CG, Halloran SP, Kuipers EJ, Seaman HE. Advances in Fecal Occult Blood Tests: the FIT revolution. Volume 60 of Issue 3. 2014. PMID: 25492500


  16. Green BB, Coronado GD, Devoe JE, Allison J. Navigating the murky waters of colorectal cancer screening and health reform. Volume 104 of Issue 6. American journal of public health 2014. PMID: 24825195


  17. Gupta S, Sussman DA, Doubeni CA, Anderson DS, Day L, Deshpande AR, Elmunzer BJ, Laiyemo AO, Mendez J, Somsouk M, Allison J, Bhuket T, Geng Z, Green BB, Itzkowitz SH, Martinez ME. Challenges and possible solutions to colorectal cancer screening for the underserved. Volume 106 of Issue 4. Journal of the National Cancer Institute 2014. PMID: 24681602


  19. Fraser CG, Allison JE, Young GP, Halloran SP, Seaman H. A standard for Faecal Immunochemical TesTs for haemoglobin evaluation reporting (FITTER). Volume 51 of Issue Pt 2. 2013. PMID: 24345727


  20. Day LW, Bhuket T, Allison J. FIT testing: an overview. Volume 15 of Issue 11. 2013. PMID: 24218070


  21. Fraser CG, Halloran SP, Allison JE, Young GP. Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT). Volume 51 of Issue 11. 2013. PMID: 23787468


  22. Li D, Collins B, Velayos FS, Liu L, Lewis JD, Allison JE, Flowers NT, Hutfless S, Abramson O, Herrinton LJ. Racial and ethnic differences in health care utilization and outcomes among ulcerative colitis patients in an integrated health-care organization. Volume 59 of Issue 2. 2013. PMID: 24173809


  23. Fraser CG, Allison JE, Young GP, Halloran SP. Quantitation of hemoglobin improves fecal immunochemical tests for noninvasive screening. Volume 11 of Issue 7. 2013. PMID: 23591278


  24. Gupta S, Tong L, Anderson P, Rose B, Carter E, Koch M, Argenbright K, Ahn C, Allison J, Skinner CS. Measurement of colorectal cancer test use with medical claims data in a safety-net health system. Volume 345 of Issue 2. 2013. PMID: 22814361


  25. Allison JE. Colorectal-cancer screening. Volume 366 of Issue 22. The New England journal of medicine 2012. PMID: 22646640


  26. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Volume 143 of Issue 2. Gastroenterology 2012. PMID: 22609382


  27. Fraser CG, Allison JE, Halloran SP, Young GP. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. Volume 104 of Issue 11. 2012. PMID: 22472305


  28. Fraser CG, Allison JE, Young GP, Halloran SP. Newer fecal tests: opportunities for professionals in laboratory medicine. Volume 58 of Issue 6. 2012. PMID: 22452971


  29. Allison JE, Fraser CG, Halloran SP, Young GP. Comparing fecal immunochemical tests: improved standardization is needed. Volume 142 of Issue 3. Gastroenterology 2012. PMID: 22281273


  30. Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Volume 106 of Issue 12. 2011. PMID: 22031357


  31. Allison JE, Fraser CG. ACP Journal Club. Fecal immunochemical tests had better sensitivity for detecting colorectal neoplasia in aspirin users than in nonusers. Volume 154 of Issue 8. Annals of internal medicine 2011. PMID: 21502636


  33. Velayos FS, Liu L, Lewis JD, Allison JE, Flowers N, Hutfless S, Abramson O, Perry GS, Herrinton LJ. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Volume 139 of Issue 5. Gastroenterology 2010. PMID: 20659470


  34. Abramson O, Durant M, Mow W, Finley A, Kodali P, Wong A, Tavares V, McCroskey E, Liu L, Lewis JD, Allison JE, Flowers N, Hutfless S, Velayos FS, Perry GS, Cannon R, Herrinton LJ. Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. Volume 157 of Issue 2. The Journal of pediatrics 2010. PMID: 20400099


  35. Allison JE. Colorectal cancer screening guidelines: the importance of evidence and transparency. Volume 138 of Issue 5. Gastroenterology 2010. PMID: 20211181


  36. Allison JE. The best screening test for colorectal cancer is the one that gets done well. Volume 71 of Issue 2. 2010. PMID: 20152313


  38. Allison JE, Potter MB. New screening guidelines for colorectal cancer: a practical guide for the primary care physician. Volume 36 of Issue 3. 2009. PMID: 19616156


  39. Gupta S, Tong L, Allison JE, Carter E, Koch M, Rockey DC, Anderson P, Ahn C, Argenbright K, Skinner CS. Screening for colorectal cancer in a safety-net health care system: access to care is critical and has implications for screening policy. Volume 18 of Issue 9. 2009. PMID: 19745221


  41. Herrinton LJ, Liu L, Fireman B, Lewis JD, Allison JE, Flowers N, Hutfless S, Velayos FS, Abramson O, Altschuler A, Perry GS. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Volume 137 of Issue 2. Gastroenterology 2009. PMID: 19445944


  42. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, Devens ME, Harrington JJ, Hillman SL. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Volume 149 of Issue 7. Annals of internal medicine 2008. PMID: 18838724


  43. Allison J, Herrinton LJ, Liu L, Yu J, Lowder J. Natural history of severe ulcerative colitis in a community-based health plan. Volume 6 of Issue 9. 2008. PMID: 18774533


  44. Pressman AR, Hutfless S, Velayos F, Fireman B, Lewis JD, Allison J, Abramson O, Herrinton LJ. Patterns of infliximab use among Crohn's disease patients in a community setting. Volume 14 of Issue 9. Inflammatory bowel diseases 2008. PMID: 18452199


  45. Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Volume 103 of Issue 8. 2008. PMID: 18796097


  46. Altschuler A, Collins B, Lewis JD, Velayos F, Allison JE, Hutfless S, Liu L, Herrinton LJ. Gastroenterologists' attitudes and self-reported practices regarding inflammatory bowel disease. Volume 14 of Issue 7. Inflammatory bowel diseases 2008. PMID: 18300277


  47. Hutfless SM, Weng X, Liu L, Allison J, Herrinton LJ. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Volume 133 of Issue 6. Gastroenterology 2007. PMID: 18054550


  48. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. Volume 99 of Issue 19. 2007. PMID: 17895475


  49. Allison JE. Should recommendations for colorectal-cancer screening be changed? Volume 4 of Issue 7. 2007. PMID: 17519918


  50. Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization. Volume 102 of Issue 7. 2007. PMID: 17437504


  51. Herrinton LJ, Liu L, Lafata JE, Allison JE, Andrade SE, Korner EJ, Chan KA, Platt R, Hiatt D, O'Connor S. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Volume 13 of Issue 4. Inflammatory bowel diseases 2007. PMID: 17219403


  52. Allison JE, Lawson M. Screening tests for colorectal cancer: a menu of options remains relevant. Volume 8 of Issue 6. Current oncology reports 2006. PMID: 17040627


  53. Allison JE. Colon Cancer Screening Guidelines 2005: the fecal occult blood test option has become a better FIT. Volume 129 of Issue 2. Gastroenterology 2005. PMID: 16083728


  54. Allison JE. Immunochemical fecal occult blood tests for colorectal cancer screening. Volume 116 of Issue 7. The American journal of medicine 2004. PMID: 15047043